| abstract |
Polypeptide conjugates with G-CSF activity are provided comprising a polypeptide having at least one lysine residue introduced and at least one lysine residue removed, as compared to the human G-CSF sequence, and which are conjugated with 2 to 6 portions of polyethylene glycol; the conjugates have reduced in vitro bioactivity, a long in vivo half-life and reduced clearance mediated by the recipient, and provide faster stimulation of the production of white and neutrophilic globules than recombinant unconjugated human G-CSF. |